Prevention of measles and rubella
Conditions
Interventions
None listed
Sponsors
Mika Oshio
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Born between April 2, 2019 and April 1, 2020, and joined L0131 study at 1st routine immunization and got thier antibody titer measured after the vaccination 2) Assent given by the subjects and Infomed consent signed by their parents or gurdians
Exclusion criteria
Exclusion criteria: 1) Received booster dose of vaccine prepared from measles virus and/or rubella virus 2) Received a blood transfusion or gamma-globulin preparation within 12 weeks (Day -84), or high-dose therapy of gamma-globulin preparation (200 mg/kg/day or more) within 24 weeks (Day -168) prior to the blood sampling 3) PI(SI) identified as Not eligiable to participate in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1) Seropositive rate of neutralizing antibody against measles virus and hemagglutination inhibition (HI) antibody against rubella | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) Geometric mean antibody titers of neutralizing antibody against measles virus and hemagglutination inhibition (HI) antibody against rubella 2) Transition of neutralizing antibody titer aginst measles virus and hemagglutination inhibition (HI) antibody titer against rubella from the post of 1st vaccination to the pre of 2nd vaccination | — |
Contacts
Public ContactOshio Mika
The Research Foundation for Microbial Diseases of Osaka University
Outcome results
None listed